

Yhdistynyt kuningaskunta-Bristol: Patologiset tutkimuspalvelut

OJ S 21/2020 30/01/2020

Vapaaehtoista ennakkoavoimuutta (ex ante) koskeva ilmoitus

Palvelut

**Oikeusperusta:**

Direktiivi 2014/24/EU

## I kohta: Hankintaviranomaisen/-yksikkö

---

### I.1. Nimi ja osoitteet

Virallinen nimi: North Bristol NHS Trust

Postiosoite: Southmead Road, Bristol

Postitoimipaikka: Bristol

NUTS-koodi: UKK11 Bristol, City of

Postinumero: BS10 5NB

Maa: Yhdistynyt kuningaskunta

Yhteyshenkilö: Martin Strawson

Sähköpostiosoite: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

Puhelin: +44 1173420815

**Internetiosoite (-osoitteet):**

Pääasiallinen osoite: <https://www.nbt.nhs.uk/>

### I.4. Hankintaviranomaisen tyyppi

Muu tyyppi: NHS trust

### I.5. Pääasiallinen toimiala

Terveystieteiden tutkimus

## II kohta: Kohde

---

### II.1. Hankinnan laajuus

#### II.1.1. Nimi

Procurement of a Large Throughput DNA Sequencer

Viitenumero: BWPCCL001501

#### II.1.2. Pääasiallinen CPV-koodi

85111800 Patologiset tutkimuspalvelut

#### II.1.3. Sopimuksen tyyppi

Palvelut

#### II.1.4. Lyhyt kuvaus

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

#### **II.1.6. Osia koskevat tiedot**

Tämä sopimus on jaettu osiin: ei

#### **II.1.7. Hankinnan kokonaisarvo**

Arvo ilman alv:tä: 779 625,00 GBP

### **II.2. Kuvaus**

#### **II.2.2. CPV-lisäkoodi(t)**

85111000 Sairaalapalvelut

#### **II.2.3. Suorituspaikka**

NUTS-koodi: UKK11 Bristol, City of

#### **II.2.4. Kuvaus hankinnasta**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **II.2.5. Hankintasopimuksen tekoperusteet**

Laatuperuste - Nimi: Quality / Painotus: 90

Hinta - Painotus: 10

#### **II.2.11.**

## **Tietoa lisähankintamahdollisuuksista**

Lisähankintamahdollisuudet: ei

### **II.2.13. Tietoa Euroopan unionin rahastoista**

Hankinta liittyy Euroopan unionin varoin rahoitettavaan hankkeeseen ja/tai ohjelmaan: ei

### **II.2.14. Lisätiedot**

## **IV kohta: Menettely**

---

### **IV.1. Kuvaus**

#### **IV.1.1. Menettelyn luonne**

Sopimuksen tekeminen ilman ennakkoon Euroopan unionin virallisessa lehdessä julkaistua tarjouskilpailukutsua jäljempänä luetelluissa tapauksissa

- Hankinta ei kuulu direktiivin soveltamisalaan

Selitys:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **IV.1.3. Tietoa puitejärjestelystä**

#### **IV.1.8. Tietoa WTO:n julkisia hankintoja koskevasta sopimuksesta (GPA)**

Hankintaan sovelletaan julkisia hankintoja koskevaa sopimusta: ei

### **IV.2. Hallinnolliset tiedot**

## V kohta: Sopimuksen/käyttöoikeussopimuksen tekeminen

---

**Nimi:**

Procurement of Large High Throughput DNA Sequencer

### V.2. Sopimuksen/käyttöoikeussopimuksen tekeminen

#### V.2.1. Hankintasopimusta koskevan päätöksen päivämäärä

28/01/2020

#### V.2.2. Tietoa tarjouksista

Sopimus on tehty taloudellisten toimijoiden ryhmän kanssa: ei

#### V.2.3. Sopimuskumppanin/käyttöoikeussopimuksen saajan nimi ja osoite

Virallinen nimi: Illumina Cambridge Ltd

Postiosoite: Chesterford Research Park, Little Chesterford

Postitoimipaikka: Saffron Walden

NUTS-koodi: UKI London

Postinumero: CB10 1XL

Maa: Yhdistynyt kuningaskunta

Tuleva sopimuskumppani/käyttöoikeussopimuksen saaja on pk-yritys: kyllä

#### V.2.4. Tiedot sopimuksen/osan/käyttöoikeussopimuksen arvosta

Sopimuksen/osan/käyttöoikeussopimuksen kokonaisarvo: 779 625,00 GBP

#### V.2.5. Tietoa alihankinnasta

## VI kohta: Täydentävät tiedot

---

### VI.3. Lisätiedot

### VI.4. Muutoksenhakumenettelyt

#### VI.4.1. Muutoksenhakuelin

Virallinen nimi: Bristol and Weston Purchasing Consortium

Postiosoite: Level 3, Whitefriars, Lewins Mead

Postitoimipaikka: Bristol

Postinumero: BS1 2NT

Maa: Yhdistynyt kuningaskunta

Sähköpostiosoite: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

#### VI.4.2. Sovittelusta vastaava elin

Virallinen nimi: Bristol and Weston Purchasing Consortium

Postiosoite: Level 3, Whitefriars, Lewins Mead

Postitoimipaikka: Bristol

Postinumero: BS1 2NT

Maa: Yhdistynyt kuningaskunta

#### VI.4.4. Yksikkö, josta saa tietoa muutoksenhakumenettelystä

Virallinen nimi: Bristol and Weston Purchasing Consortium

Postiosoite: Level 3, Whitefriars, Lewins Mead

Postitoimipaikka: Bristol

Postinumero: BS1 2NT

Maa: Yhdistynyt kuningaskunta

**VI.5. Tämän ilmoituksen lähettämispäivä**

28/01/2020